Scanner

The strongest stocks and groups. RS rating is O'Neil's: 12-month price change with the latest quarter counted double, ranked 1 to 99 against every US stock above $1 trading at least $1M a day.

Period

37 stocks · 3,706 ranked · close of Fri, Nov 20

StockPrice1MRSInd RSGroup1W3M6M12MADR$ VolOff high
REPLBiotech19.07+59.0%9996Smaller lossSmaller loss-8/43-12.9%+29.6%+288.4%+112.1%8.8%$66.7M19%
VCELBiotech57.52+33.9%9589+170%▲To profit+27%▲+23%8/43+1.0%+36.0%+65.6%+47.7%4.9%$50.8M4%
CGONBiotech79.47+27.1%91▲80Bigger lossBigger loss-4%First sales8/43+6.8%+1.6%+23.7%+86.5%7.9%$148M15%
ADMABiotech13.17+20.3%8670+47%▲+14%+5%▲+2%8/43-3.7%+37.9%+59.8%-17.4%5.4%$52.3M36%
SRRKBiotech48.13+14.7%56▲48Smaller lossSmaller lossFirst sales8/43+11.4%-17.3%0.0%+21.3%5.8%$78.8M22%
ADPTBiotech27.93+14.4%9690-67%Bigger loss-11%+22%8/43-3.8%+9.3%+101.2%+84.4%6.3%$66.9M13%
KODBiotech97.17+13.3%9997Smaller lossBigger loss-8/43-12.6%+161.1%+168.2%+397.5%6.7%$84.2M14%
COAGBiotech39.29+12.8%72▲58Smaller lossSmaller loss-8/43-3.8%-15.8%+51.8%-8.8%$20.9M-
IMVTBiotech31.77+9.2%58▼50Smaller lossBigger loss-8/43-7.0%-26.7%-7.0%+37.2%4.6%$43.5M30%
KYMRBiotech115.31+4.0%9179Bigger lossSmaller loss-100%+466%8/43-9.6%-4.7%+46.2%+77.9%6.0%$130M19%
VORBiotech19.19+1.3%92▲85Smaller lossSmaller loss-8/43-1.2%-15.5%+33.9%+145.4%6.7%$14.9M26%
TARSBiotech73.01+1.3%67▼54Bigger lossSmaller loss+64%+69%8/43-9.1%+0.3%+17.3%-5.3%5.4%$60.4M20%
ICLRBiotech186.71+0.7%9284To profit-63%-3%+1%8/43-4.1%+7.6%+59.9%+17.6%4.1%$244M15%
DNLIBiotech18.45-1.1%42▲43To profitSmaller lossFirst salesFirst sales8/43-1.6%-23.8%-1.0%+9.0%4.6%$31.8M32%
MAZEBiotech31.37-1.8%56▼49Bigger lossSmaller loss-8/43-8.6%+6.0%+21.7%-11.7%5.8%$20.8M42%
MRNABiotech195.00-3.8%9998To profitSmaller loss+29%▲+2%8/43-12.7%+40.4%+316.0%+706.5%8.3%$2.4B31%
BCRXBiotech7.22-7.2%3839+133%+1400%+13%+34%8/43-5.1%-25.4%-12.9%+4.2%4.5%$40.6M36%
CRLBiotech314.32-7.5%9791+524%▲-103%-2%-3%8/43-7.0%+5.3%+96.1%+94.5%4.8%$370M17%
RGENBiotech163.81-8.3%7661-362%-65%+11%+12%8/43-2.4%-9.8%+42.4%+5.6%4.7%$214M18%
PCVXBiotech55.39-11.9%61▼51Bigger lossBigger loss-8/43-12.6%-10.5%+17.1%+13.9%4.8%$96.7M39%
RLAYBiotech16.12-12.1%9487Smaller lossBigger loss-8/43-10.9%-18.4%+19.1%+154.3%6.7%$49.4M24%
FDMTBiotech10.23-13.7%43▼44Bigger lossBigger loss+4506%+25K%8/43-16.4%-33.5%+18.9%-5.3%8.1%$10.7M40%
RVMDBiotech161.20-14.1%9177Bigger lossBigger lossFirst sales8/43-6.4%-23.8%+6.4%+128.6%5.1%$476M28%
BEAMBiotech20.90-14.9%2835Bigger lossBigger loss-97%-94%8/43-8.4%-26.2%-27.0%-0.4%7.6%$62.5M45%
IMCRBiotech26.41-17.8%26▼30Bigger lossSmaller loss-1%+18%8/43-11.8%-27.9%-8.4%-31.7%4.9%$14.5M35%
VIRBiotech8.39-19.6%70▼57Smaller lossTo profit-178%+20K%8/43-15.8%-15.3%-8.7%+54.2%6.6%$34.6M42%
ABSIBiotech7.51-19.9%9792Smaller lossSmaller loss-20%-46%8/43-11.1%-15.1%+47.3%+162.6%11.1%$45.5M40%
CRSPBiotech39.10-21.8%2225Smaller lossSmaller loss+1325%▲+1041%8/43-7.4%-31.5%-22.4%-22.9%5.6%$95.6M38%
GLUEBiotech8.64-22.2%1014-+326%▲-61%8/43-7.8%-37.3%-54.1%-38.9%5.8%$14.2M67%
DNABiotech7.46-23.2%55▼47Smaller lossSmaller loss-6%-49%8/43-22.4%+10.0%-11.3%-5.7%13.4%$27.8M59%
TWSTBiotech103.32-23.7%9895Smaller loss-270%+28%▲+23%8/43-7.4%-26.6%+70.6%+306.0%11.9%$326M53%
NVAXBiotech7.47-25.2%42▼42Smaller loss-152%-3%-76%8/43-12.4%-15.7%-18.9%+17.8%7.4%$53.3M44%
IBRXBiotech6.02-27.6%8365Bigger lossBigger loss+52%+94%8/430.0%-20.6%-16.6%+181.3%7.9%$95.1M52%
INBXBiotech68.97-29.0%24▼28Bigger lossBigger lossFirst sales-100%8/43-17.2%-34.3%-31.9%-16.0%10.3%$25.9M56%
CADLBiotech5.04-39.9%2123Bigger lossBigger loss-8/43-18.7%-60.8%-36.9%+14.0%9.3%$11.7M64%
CGEMBiotech8.89-40.4%1519--8/43-13.5%-59.3%-35.8%+5.2%9.6%$11.2M62%
IOVABiotech6.90-51.2%9893Smaller lossSmaller loss+80%▲+66%8/43-11.1%-14.4%+67.9%+205.3%8.5%$136M55%

RS rating: 0.4 × 3-month + 0.2 × 6-month + 0.2 × 9-month + 0.2 × 12-month return, ranked 1 to 99. Stocks under a year old use the quarters they have. Ind RS ranks the same score among stocks in the same industry. Groups come from SEC SIC codes and need at least 3 stocks. A blue dot means the RS line (price against SPY) is at a 52-week high, a ringed one that it got there before the price. ADR is the 20-day average of high divided by low, minus 1. Updated after each close.

EPS and revenue growth come from the companies' own SEC filings (XBRL): the latest reported quarter against the same quarter a year earlier, with the quarter before under it and ▲ when growth sped up. EPS is diluted GAAP, not the adjusted figure in press releases. There is no percent off a loss or off zero sales; a move to profit or to first sales counts as 0% when sorting and filtering. Q4 is the fiscal year minus Q1 to Q3. Foreign filers (20-F) have no quarterly data. Filings through Sat, Nov 21.